Indonesia IVD Market (2022-2029)
The Indonesia IVD Market is expected to reach $1.11 billion by 2029, at a CAGR of 10.6% from 2022 to 2029.
- Published
- Sep 2022
- Pages
- 160
- Format
- PDF + Excel
- Report ID
- MRHC - 104668
- Base year
- 2021
- 2029 · FORECAST
- $1.11B
- 2029
- $1.11B
- CAGR 2022–2029
- 10.6%
2021 baseline · 2022–2029 forecast at 10.6% CAGR · hover a bar for the value
Key highlights
In 2022, the molecular diagnostics segment is slated to register the highest CAGR during the forecast period
The reagent, assays, and kits segment is projected to register the highest CAGR during the forecast period
The oncology segment is projected to register the fastest growth during the forecast period
The home care/self-testing segment is slated to register the highest CAGR during the forecast period
Indonesia’s Rising Healthcare Spending to Offer Significant Growth Opportunities for Players Operating in the Indonesia IVD Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2021 |
| Estimated Year | 2022 |
| Forecast Period | 2022–2029 |
| Market Size (2029) | USD 1.11 billion |
| CAGR (2022–2029) | 10.6% |
| Format | PDF, Excel & Cloud Portal · 160 pages |
| Segments Covered | By Product: Reagents, Assays, and Kits, Analyzers/Instruments, Software & Services · By Technology: Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology, Coagulation & Hemostasis, Electrolyte Analysis, Diabetes/Glucose Monitoring, Urinalysis · By Application: Infectious Diseases, Diabetes, Oncology, Cardiology · By End User: Hospital Laboratories, Clinical Laboratories Large/Reference Laboratories, Medium-sized Laboratories, Small-sized Laboratories |
| Key Companies | F. Hoffman-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Qiagen N.V., Siemens Healthineers AG, Sysmex Corporation |
Report overview
Segments covered: product, technology, application, end user.
The growth of this market is driven by the high prevalence of infectious and chronic diseases and the growing awareness regarding the importance of early disease diagnosis. Furthermore, Indonesia’s rising health spending and the growing scope for foreign investments are expected to create significant growth opportunities for the players operating in this market. However, the shortage of healthcare professionals and the high prices of advanced IVD products are major challenges for market growth.
The COVID-19 pandemic negatively impacted the Indonesia IVD market in the initial phase of the pandemic, as the Government imposed lockdowns and various restrictions to curb the spread of the virus. Domestic and international air & sea travel was banned. Restrictions were placed on public events, and schools and other educational institutions were closed temporarily. Consequently, the country’s GDP declined by 0.7% in Q1 2021 compared to Q1 2020 (Source: International Monetary Fund). The shrinking GDP negatively impacted businesses and industries, including healthcare. Moreover, the lockdowns and restrictions imposed during the initial stages of the pandemic disrupted supply chains, negatively impacting the Indonesia IVD market. Non-priority diagnostic procedures had to be postponed or canceled due to the overburdening of hospitals, clinics, and diagnostic laboratories, temporarily hindering the growth of Indonesia’s IVD market.
However, in the later stages of the pandemic, the Government of Indonesia took initiatives to boost COVID-19 testing in the country. The government distributed PCR machines, PCR kits, and other consumables. Furthermore, the Government-designated laboratories for COVID-19 testing increased. The number of laboratories designated to test for COVID-19 increased to 742 by May 2021, compared to 466 laboratories in November 2020. These initiatives boosted the growth of the IVD market in Indonesia.
Report infographic
Table of contents
11 chapters · 88 sections · 160 pages · click to expandSegmental analysis
By Technology
- The molecular diagnostics segment is slated to register the highest CAGR during the forecast period
- The segment's growth can be attributed to the initiatives by the Government, private players, and institutions to support the development of molecular diagnostics and the constant innovations and advancements in molecular technologies.
By Product
- The reagent, assays, and kits segment is projected to register the highest CAGR during the forecast period
- The rising adoption of point-of-care tests, the rising prevalence of chronic & infectious diseases, and the increasing launches of disease-specific kits are the key factors contributing to the demand for consumables.
- Furthermore, the COVID-19 pandemic significantly boosted the demand for IVD reagents, assays, and kits in the country.
By Application
- The oncology segment is projected to register the fastest growth during the forecast period
- The growth of this segment is driven by the increasing incidence rate of cancer in the country.
- According to International Agency for Research on Cancer, in 2020, 396,914 new cancer cases were reported in Indonesia, which is estimated to increase to 522,246 by 2030.
- The home care/self-testing segment is slated to register the highest CAGR during the forecast period
- The rising availability of home test kits for several diseases, the rising aging population, the rising awareness among patients about self-testing kits, and the ongoing transition from hospital to home health care to curtail the rising costs are the factors driving the growth of this segment.
- The emergence of accessible and affordable self-testing kits and the high prevalence of diseases that can be self-monitored such as diabetes & COVID-19, are expected to increase the adoption of home care/self-testing kits during the forecast period.
Geographic analysis
Asia-Pacific
Indonesia started rapidly increasing its healthcare spending after the outbreak of the COVID-19 pandemic, which was a necessary measure to effectively vaccinate and manage the country’s large population. Indonesia’s annual health spending has increased from $8.07 billion (Rp 113.6 trillion) in 2019 to $17.62 billion (Rp 255.3 trillion) in 2022 (Source: Indonesia’s Finance Ministry). This significant increase in health spending was mainly for diagnostics, testing & tracing, health equipment, COVID-19 hospital treatment, and financial incentives for healthcare workers. Indonesia’s increasing health spending is aimed at improving the country’s healthcare infrastructure and acquiring advanced In vitro diagnostic technologies to improve testing capabilities. Thus, Indonesia’s rising health spending is expected to create significant growth opportunities for the players operating in the IVD market in Indonesia. Indonesia’s Rising Healthcare Spending to Offer Significant Growth Opportunities for Players Operating in the Indonesia IVD Market
Competitive landscape
- F. Hoffman-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- PerkinElmer, Inc.
- Qiagen N.V.
- Siemens Healthineers AG
- Sysmex Corporation
Frequently asked questions
The study covers the market sizes & forecasts of the Indonesia IVD market based on product, technology, application, and end user. This report also involves the value analysis of various segments and subsegments of the Indonesia IVD Market.
Cite this report
Meticulous Research. (2022). Indonesia IVD Market - Opportunity Analysis And Industry Forecast (2022-2029) (Report No. MRHC - 104668). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/indonesia-ivd-market-5352